REPLIGEN CORP Deferred Revenue Recognized
REPLIGEN CORP (RGEN) reported Deferred Revenue Recognized of $9.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-07-29
- REPLIGEN CORP contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $6.20M, a 16.98% increase year-over-year.
- REPLIGEN CORP contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $5.30M.
- REPLIGEN CORP contract with customer, liability, revenue recognized for fiscal 2025 was $10.40M, a 36.59% decline from fiscal 2024.
- REPLIGEN CORP contract with customer, liability, revenue recognized for fiscal 2024 was $16.40M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.60M 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | $6.20M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $10.40M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $9.90M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $8.50M 10-Q · filed 2026-07-29 | |||
| 2025-03-31 | $5.30M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $16.40M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $15.40M 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |